[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] 陈琪,陆建,郭金和.晚期非小细胞肺癌免疫治疗研究进展[J].东南大学学报(医学版),2021,40(4):536-541.
[3] HERBST R S,MORGENSZTERN D,BOSHOFF C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.
[4] OUDKERK M,LIU S,HEUVELMANS M A,et al.Lung cancer LDCT screening and mortality reduction-evidence,pitfalls and future perspectives[J].Nat Rev Clinl Oncol,2021,18(3):135-151.
[5] SKOULIDIS F,HEYMACH J V.Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy[J].Nat Rev Cancer,2019,19(9):495-509.
[6] 李汉杰,葛鹏,景瑞军,等.TGF-β通过激活smad2信号通路上调CXCR4表达促进非小细胞肺癌A549细胞迁移和侵袭[J].现代医学,2019,47(5):555-560.
[7] DING L,GETZ G,WHEELER D A,et al.Somatic mutations affect key pathways in lung adenocarcinoma[J].Nature,2008,455(7216):1069-1075.
[8] GOTTLIEB T M,OREN M.p53 in growth control and neoplasia[J].Biochim Biophys Acta,1996,1287(2-3):77-102.
[9] CANDAU R,SCOLNICK D M,DARPINO P,et al.Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity[J].Oncogene,1997,15(7):807-816.
[10] WALKER K K,LEVINE A J.Identification of a novel p53 functional domain that is necessary for efficient growth suppression[J].Proc Natl Acad Sci U S A,1996,93(26):15335-15340.
[11] PAVLETICH N P,CHAMBERS K A,PABO C O.The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots[J].Genes Dev,1993,7(12B):2556-2564.
[12] VEPRINTSEV D B,FREUND S M,ANDREEVA A,et al.Core domain interactions in full-length p53 in solution[J].Proc Natl Acad Sci U S A,2006,103(7):2115-2119.
[13] GU W,ROEDER R G.Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain[J].Cell,1997,90(4):595-606.
[14] HANCOCK J F,MAGEE A I,CHILDS J E,et al.All ras proteins are polyisoprenylated but only some are palmitoylated[J].Cell,1989,57(7):1167-1177.
[15] KANG R,KROEMER G,TANG D.The tumor suppressor protein p53 and the ferroptosis network[J].Free Radic Biol Med,2019,133:162-168.
[16] KRUISWIJK F,LABUSCHAGNE C F,VOUSDEN K H.p53 in survival,death and metabolic health:a lifeguard with a licence to kill[J].Nat Rev Mol Cell Biol,2015,16(7):393-405.
[17] FARKAS T,HANSEN K,HOLM K,et al.Distinct phosphorylation events regulate p130-and p107-mediated repression of E2F-4[J].J Biol Chem,2002,277(30):26741-26752.
[18] SULLIVAN K D,GALBRAITH M D,ANDRYSIK Z,et al.Mechanisms of transcriptional regulation by p53[J].Cell Death Differ,2018,25(1):133-143.
[19] OREN M,ROTTER V.Mutant p53 gain-of-function in cancer[J].Cold Spring Harb Perspect Biol,2010,2(2):a001107.
[20] GHOSH M,SAHA S,BETTKE J,et al.Mutant p53 suppresses innate immune signaling to promote tumorigenesis[J].Cancer Cell,2021,39(4):494-508.
[21] HAO X L,HAN F,ZHANG N,et al.TC2N,a novel oncogene,accelerates tumor progression by suppressing p53 signaling pathway in lung cancer[J].Cell Death Differ,2019,26(7):1235-1250.
[22] YANG D,CHENG D,TU Q,et al.HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53[J].Theranostics,2018,8(13):3517-3529.
[23] HUNCHAREK M,MUSCAT J,GESCHWIND J F.K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer:a combined analysis of 881 cases[J].Carcinogenesis,1999,20(8):1507-1510.
[24] HINGORANI S R,PETRICOIN E F,MAITRA A,et al.Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse[J].Cancer Cell,2003,4(6):437-450.
[25] KRANENBURG O.The KRAS oncogene:past,present,and future[J].Biochim Biophys Acta,2005,1756(2):81-82.
[26] MCCOY M S,TOOLE J J,CUNNINGHAM J M,et al.Characterization of a human colon/lung carcinoma oncogene[J].Nature,1983,302(5903):79-81.
[27] MASCAUX C,IANNINO N,MARTIN B,et al.The role of RAS oncogene in survival of patients with lung cancer:a systematic review of the literature with meta-analysis[J].Br J Cancer,2005,92(1):131-139.
[28] SANTOS E,MARTIN-ZANCA D,REDDY E P,et al.Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient[J].Science,1984,223(4637):661-664.
[29] CLAYTON S J,SCOTT F M,WALKER J,et al.K-ras point mutation detection in lung cancer:comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification[J].Clin Chem,2000,46(12):1929-1938.
[30] CANON J,REX K,SAIKI A Y,et al.The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity[J].Nature,2019,575(7781):217-223.
[31] HALLIN J,ENGSTROM L D,HARGIS L,et al.The KRAS (G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J].Cancer Discov,2020,10(1):54-71.
[32] AARONSON S A.Growth factors and cancer[J].Science,1991,254(5035):1146-1153.
[33] ULLRICH A,SCHLESSINGER J.Signal transduction by receptors with tyrosine kinase activity[J].Cell,1990,61(2):203-212.
[34] OLAYIOYE M A,NEVE R M,LANE H A,et al.The ErbB signaling network:receptor heterodimerization in development and cancer[J].EMBO J,2000,19(13):3159-3167.
[35] SHARMA S V,BELL D W,SETTLEMAN J,et al.Epidermal growth factor receptor mutations in lung cancer[J].Nat Rev Cancer,2007,7(3):169-181.
[36] GAZDAR A F,SHIGEMATSU H,HERZ J,et al.Mutations and addiction to EGFR:the achilles 'heal' of lung cancers?[J].Trends Mol Med,2004,10(10):481-486.
[37] FUKUOKA M,YANO S,GIACCONE G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial)[J].J Clin Oncol,2003,21(12):2237-2246.
[38] KRIS M G,NATALE R B,HERBST R S,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA,2003,290(16):2149-2158.
[39] SHEPHERD F A,RODRIGUES P J,CIULEANU T,et al.Erlotinib in previously treated non-small-cell lung cancer[J].N Engl J Med,2005,353(2):123-132.
[40] CHENG S,QIAN F,HUANG Q,et al.HOXA4,down-regulated in lung cancer,inhibits the growth,motility and invasion of lung cancer cells[J].Cell Death Dis,2018,9(5):465.
[41] GAO L,HU Y,TIAN Y,et al.Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition[J].Nat Commun,2019,10(1):1665.
[42] KHALID A B,PENCE J,SUTHON S,et al.GATA4 regulates mesenchymal stem cells via direct transcriptional regulation of the WNT signalosome[J].Bone,2021,144:115819.
[43] STAVNIICHUK R,DELAFOREST A,THOMPSON C A,et al.GATA4 blocks squamous epithelial cell gene expression in human esophageal squamous cells[J].Sci Rep,2021,11(1):3206.
[44] KOHLER B,LIN L,FERRAZ-DE-SOUZA B,et al.Five novel mutations in steroidogenic factor 1(SF1,NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency[J].Hum Mutat,2008,29(1):59-64.
[45] WHITE R A,DOWLER L L,PASZTOR L M,et al.Assignment of the transcription factor GATA4 gene to human chromosome 8 and mouse chromosome 14:Gata4 is a candidate gene for Ds (disorganization)[J].Genomics,1995,27(1):20-26.
[46] WU Q,TIAN Y,ZHANG J,et al.In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis[J].Proc Natl Acad Sci U S A,2018,115(17):E3978-E3986.
[47] GREENFIELD A,CARREL L,PENNISI D,et al.The UTX gene escapes X inactivation in mice and humans[J].Hum Mol Genet,1998,7(4):737-742.
[48] LEE M G,VILLA R,TROJER P,et al.Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination[J].Science,2007,318(5849):447-450.
[49] YUAN G,FLORES N M,HAUSMANN S,et al.Elevated NSD3 histone methylation activity drives squamous cell lung cancer[J].Nature,2021,590(7846):504-508.
[50] STEC I,NAGL S B,VAN OMMEN G J,et al.The PWWP domain:a potential protein-protein interaction domain in nuclear proteins influencing differentiation?[J].FEBS Lett,2000,473(1):1-5.
[51] PASTUSHENKO I,MAURI F,SONG Y,et al.Fat1 deletion promotes hybrid EMT state,tumour stemness and metastasis[J].Nature,2021,589(7842):448-455.
[52] CAMPBELL P J,GETZ G,KORBEL J O,et al.Pan-cancer analysis of whole genomes[J].Nature,2020,578(7793):82-93.
[53] SÁNCHEZ-DANÉS A,BLANPAIN C.Deciphering the cells of origin of squamous cell carcinomas[J].Nat Rev Cancer,2018,18(9):549-561. |
